Lauren R Schaff1, Christian Grommes2,3. 1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. GrommesC@mskcc.org. 3. , New York, USA. GrommesC@mskcc.org.
Abstract
PURPOSE OF REVIEW: Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy confined to the brain, spinal cord, leptomeninges, and eyes. Due to its rarity, there is a paucity of randomized trials and a varied approach to its management in the oncologic community. This review summarizes recent literature guiding current clinical practice. RECENT FINDINGS: The presentation, work up, and management of PCNSL are discussed. Induction therapy incorporates a methotrexate-based chemotherapy regimen and is generally followed by a consolidation regimen including high dose chemotherapy (with or without autologous stem cell rescue). Whole brain radiation therapy (WBRT) is a potential additional consolidation strategy. Management of relapsed and refractory disease poses a special challenge due to poor outcomes. Immunotherapy and targeted treatments are promising novel strategies for recurrent/refractory patients. Currently, there is little consensus in the management of PCNSL. Treatment recommendations should be tailored to the individual patient, with consideration for risk of neurotoxicity. New, exciting strategies are in development and when feasible, enrollment in a clinical trial should be considered.
PURPOSE OF REVIEW: Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy confined to the brain, spinal cord, leptomeninges, and eyes. Due to its rarity, there is a paucity of randomized trials and a varied approach to its management in the oncologic community. This review summarizes recent literature guiding current clinical practice. RECENT FINDINGS: The presentation, work up, and management of PCNSL are discussed. Induction therapy incorporates a methotrexate-based chemotherapy regimen and is generally followed by a consolidation regimen including high dose chemotherapy (with or without autologous stem cell rescue). Whole brain radiation therapy (WBRT) is a potential additional consolidation strategy. Management of relapsed and refractory disease poses a special challenge due to poor outcomes. Immunotherapy and targeted treatments are promising novel strategies for recurrent/refractory patients. Currently, there is little consensus in the management of PCNSL. Treatment recommendations should be tailored to the individual patient, with consideration for risk of neurotoxicity. New, exciting strategies are in development and when feasible, enrollment in a clinical trial should be considered.
Entities:
Keywords:
PCNSL; Primary CNS lymphoma; Primary central nervous system lymphoma; Treatment
Authors: Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter Journal: Blood Date: 2015-01-07 Impact factor: 22.113
Authors: Douglas E Ney; Anne S Reiner; Katherine S Panageas; Hayley S Brown; Lisa M DeAngelis; Lauren E Abrey Journal: Cancer Date: 2010-10-01 Impact factor: 6.860
Authors: Patrick Roth; Peter Martus; Philipp Kiewe; Robert Möhle; Hermann Klasen; Michael Rauch; Alexander Röth; Stephan Kaun; Eckhard Thiel; Agnieszka Korfel; Michael Weller Journal: Neurology Date: 2012-08-15 Impact factor: 9.910
Authors: M Reni; A J Ferreri; N Guha-Thakurta; J Y Blay; S Dell'Oro; P Biron; F H Hochberg Journal: Int J Radiat Oncol Biol Phys Date: 2001-10-01 Impact factor: 7.038
Authors: B Kasenda; A J M Ferreri; E Marturano; D Forst; J Bromberg; H Ghesquieres; C Ferlay; J Y Blay; K Hoang-Xuan; E J Pulczynski; A Fosså; Y Okoshi; S Chiba; K Fritsch; A Omuro; B P O'Neill; O Bairey; S Schandelmaier; V Gloy; N Bhatnagar; S Haug; S Rahner; T T Batchelor; G Illerhaus; M Briel Journal: Ann Oncol Date: 2015-02-20 Impact factor: 32.976
Authors: Hendrik Pels; Annika Juergens; Axel Glasmacher; Holger Schulz; Andreas Engert; Michael Linnebank; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Monika Lamprecht; Peter Hau; Martina Deckert; Rolf Fimmers; Christopher Bangard; Ingo G H Schmidt-Wolf; Uwe Schlegel Journal: J Neurooncol Date: 2008-10-18 Impact factor: 4.130
Authors: C Schultz; C Scott; W Sherman; B Donahue; J Fields; K Murray; B Fisher; R Abrams; J Meis-Kindblom Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544
Authors: Moritz Bewarder; Maximilian Kiefer; Clara Moelle; Lisa Goerens; Stephan Stilgenbauer; Konstantinos Christofyllakis; Dominic Kaddu-Mulindwa; Natalie Fadle; Evi Regitz; Frank Neumann; Markus Hoth; Klaus-Dieter Preuss; Michael Pfreundschuh; Lorenz Thurner Journal: Front Oncol Date: 2020-11-12 Impact factor: 6.244